BioSante Pharmaceuticals, Inc. (BPAX)

[Mo-John]

Apologizes if you have already posted the link backing up the statement ( I assume you already have)
" Now the Bliss trial results is indicating that the placebo had the expected number of cardiovascular events (100%) while Libigel only had 29% of the expected CV events. "

The term "expected" in the statement leads me to believe that both test groups had pre-existing cardiovascular conditions. Assuming that both groups pre-existing conditions were similar in term of advancement of the decease, then the benefits of Libigel on CV are truly major. However, IMO what would take the wind out of those sails, if the placebo group's CV condition was more advanced than the Libigel group's CV condition and therefore the group's CV expect event did not happen within the test period. If that is the case then we are only jumping to conclusion on the CV benefits, until BPAX continues to monitor the Libigel group for CV events.

My apologizes again if I am beating a dead horse and this has been previously discussed. Thank you for sharing your information and insight; it's greatly appreciated by everyone.